Abstract Body

Background

Long-acting (LA) injectable antiretroviral therapy (ART) with cabotegravir and rilpivirine (CAB+RPV) improves convenience and quality of life for people with HIV (PWH). While its efficacy and safety have been demonstrated in clinical trials and real-world studies, administration is often limited to hospital settings, which may pose logistical barriers. The HOLA study evaluates the acceptability and safety of CAB+RPV LA administration in alternative settings in Spain—particularly in primary care and community-based centers.

Methods

HOLA is a 12-month, randomized, hybrid implementation-effectiveness, phase IV, open-label, multicenter study conducted in 9 clinical units across Catalonia and Andalusia, Spain. A total of 103 virologically suppressed PWH on or switching to CAB+RPV LA were randomized 1:1 to receive injections in hospital (Hospital Group, n=52) or in out-of-hospital settings (Outpatient Group, n=51), including primary care, community centers, and STI clinics. Clinical follow-up remained at the reference hospital. Primary outcomes included: acceptability at month 12 (mean score ≥4 on the Acceptability of Intervention Measure [AIM]) and safety (drug-related adverse events [AEs] and drug-related discontinuations). Reported statistics employed the use of the Wilcoxon rank sum test and 2-sample test for equality of proportions with continuity correction. 

Results

At month 12, acceptability was high across both groups with mean scores of 4.28 in the Hospital Group and 4.43 in the Outpatient Group (p= 0.182); 83.4% participants in the Outpatient Group displayed AIM scores ≥4, compared to 78% in the Hospital Group (p = 0.680). No virological failure (two consecutive HIV-1 RNA greater than or equal to 200 c/mL) was observed during the study. Safety data indicated a similar proportion of drug-related AEs of 40.8% in the Hospital Group compared to 56.2% in the Outpatient Group, 70% were injection site reactions; no serious AEs were reported. There was a total of one study discontinuation in the Hospital Group due to a drug-related AE and three discontinuations in the Outpatient Group due to withdrawal of informed consent.

Conclusions

Findings from the HOLA study provide critical evidence on the acceptability and safety of delivering CAB+RPV LA outside hospital settings. These data are essential to inform scalable, person-centered models of care that enhance access and convenience for PWH.